LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?

Eli Lilly's GLP-1 franchise, anchored by Mounjaro and Zepbound, delivered $27.7 billion in first-half 2026 sales, but LLY shares have fallen roughly 7% over the past month. The company's newer therapies surged 121% in Q2, while oral obesity pill Foundayo is gaining traction with major pharmacy benefit manager coverage, diversifying revenue streams beyond the core GLP-1 drugs.

Despite the momentum, LLY trades at 26.3x forward earnings, a premium valuation that reflects both growth expectations and emerging competitive threats. Novo Nordisk (NVO) and smaller biotechs including Structure Therapeutics (GPCR) and Viking Therapeutics (VKTX) are advancing oral GLP-1 candidates, intensifying pressure in the obesity treatment market.

Zacks Investment Research suggests existing LLY holders maintain positions while advising prospective investors to wait for pullbacks before entering. The recent 7% decline may represent such an opportunity, though the premium multiple leaves limited margin for execution missteps or slowing uptake in newer products.